Hyderabad, May 6 : Dr Reddy’s Laboratories Limited with its subsidiaries together on Wednesday announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the US Food and Drug Administration (USFDA).
The DDAVP injection USP brand and generic market had US sales of approximately USD 20.9 million MAT for the most recent 12 months ending in March 2020, according to IQVIA Health, a company statement here said. Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories, commented, “The launch of Desmopressin Injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company.” Dr Reddy’s Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single-dose ampoules, the statement added. (UNI)